| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/25/2001 | WO2001005384A2 Manumycin derivatives for treating parasitic disorders |
| 01/25/2001 | WO2001005383A2 Inhibition of renal uptake of radiomolecules with a combination of lysine and arginine |
| 01/25/2001 | WO2001005382A1 Synergistic composition comprising daunorubicin derivatives and antimetabolite compounds |
| 01/25/2001 | WO2001005379A1 BIODEGRADABLE POLY(ALKYLENE OXIDE)-POLY(p-DIOXANONE) BLOCK COPOLYMER SOLUBLE IN ORGANIC SOLVENTS, AND DRUG DELIVERY COMPOSITION COMPRISING SAME |
| 01/25/2001 | WO2001005378A1 Ambroxol-containing lozenge |
| 01/25/2001 | WO2001005377A1 Method for inactivating bacteria associated with bacterial vaginosis using cellulose acetate phthalate and/or hydroxypropyl methylcellulose phthalate |
| 01/25/2001 | WO2001005374A1 Methods for preparation of lipid-encapsulated therapeutic agents |
| 01/25/2001 | WO2001005373A1 Methods and apparatus for preparation of lipid vesicles |
| 01/25/2001 | WO2001005370A1 Antiadhesion barriers containing water-soluble alginate and carboxymethyl cellulose as major components and preparation method thereof |
| 01/25/2001 | WO2001005369A1 Treatment and composition for achieving skin anti-aging benefits by corneum protease activation |
| 01/25/2001 | WO2001005363A1 Sunscreen for the scalp and hair |
| 01/25/2001 | WO2001005357A1 Two-component composition for cosmetic or pharmaceutical use |
| 01/25/2001 | WO2001005356A2 Weight control product comprising a synergistic mixture of guggul extract, phosphate salt and metabolic stimulant |
| 01/25/2001 | WO2001005253A1 Compositions, kits, and methods for providing and maintaining energy and mental alertness |
| 01/25/2001 | WO2001005250A1 Potassium calcium citrate compositions and methods for production |
| 01/25/2001 | WO2001005244A1 Feeds and foods for treating or preventig disease accompanying aging, method for feeding klotho mutant homoanimal and feeds therefor |
| 01/25/2001 | WO2001005233A1 Disinfecting composition based on h2o2, acids and metal ions |
| 01/25/2001 | WO2001005232A1 Stable biocidal compositions |
| 01/25/2001 | WO2001005230A1 Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof |
| 01/25/2001 | WO2000071515A3 INHIBITORS OF FACTOR Xa |
| 01/25/2001 | WO2000071095A3 Release of poorly soluble agents |
| 01/25/2001 | WO2000068399A3 Vector-mediated delivery of integrating transposon sequences |
| 01/25/2001 | WO2000067739A3 Opioid antagonists containing compositions for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
| 01/25/2001 | WO2000067731A3 Medicinal substance utilization for preventing nitrate tolerance |
| 01/25/2001 | WO2000066587A3 Polyamines and their use in therapy |
| 01/25/2001 | WO2000066550A8 New compounds |
| 01/25/2001 | WO2000066183A8 Vascular embolic materials having multifunctions |
| 01/25/2001 | WO2000066111B1 Compositions of boswellic acids derived from boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions |
| 01/25/2001 | WO2000066093A3 Combined preparations comprising morpholine anthracyclines and anticancer agent |
| 01/25/2001 | WO2000064893A3 Thiazolidinedione derivative and its use as antidiabetic |
| 01/25/2001 | WO2000064892A3 Thiazolidinedione derivative and its use as antidiabetic |
| 01/25/2001 | WO2000063205A3 Thiazolidinedione derivative and its use as antidiabetic |
| 01/25/2001 | WO2000061174A3 Use of pegylated interferon alpha for renal cell carcinoma treatment |
| 01/25/2001 | WO2000061171A3 Uses of mammalian ox2 protein and related reagents |
| 01/25/2001 | WO2000059946A8 Hydroxymatairesinol in cancer prevention |
| 01/25/2001 | WO2000058473A3 Nucleic acids including open reading frames encoding polypeptides; 'orfx' |
| 01/25/2001 | WO2000058293A3 Glucokinase activators |
| 01/25/2001 | WO2000057837A3 Compositions and methods for effecting the levels of cholesterol |
| 01/25/2001 | WO2000056297A3 Pharmaceutical compositions comprising dipeptidy peptidase iv inhibitors for the promotion of growth |
| 01/25/2001 | WO2000056296A3 Compositions for improving fertility |
| 01/25/2001 | WO2000054756A3 Nitrate esters and their use for introducing neuroprotection and cognition enhancement |
| 01/25/2001 | WO2000053610A3 4-OXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS |
| 01/25/2001 | WO2000051585A3 Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume |
| 01/25/2001 | WO2000051577A3 Use of fluorinated triazoles for treating pain and affective or attention disorders |
| 01/25/2001 | WO2000048447A3 Composition for treatment of external secretion disorders except hypolacrimation |
| 01/25/2001 | WO2000044740A3 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
| 01/25/2001 | DE19934610A1 Rapid-release extrudates containing low viscosity hydroxypropylcellulose, useful for formulating plant protecting agents and oral pharmaceutical and veterinary compositions |
| 01/25/2001 | DE19934585A1 Treatment of dermatological disorders, e.g. pruritus, herpes simplex infection, psoriasis or acne, using tosyl chloramide salt, e.g. in ointment or gel base |
| 01/25/2001 | DE19934523A1 Transdermalsysteme zur Abgabe von Muscarin-Rezeptor-Antagonisten und ihre Verwendung zur Behandlung von Spasmen der glatten Muskulatur im urologischen Bereich Transdermal systems for the delivery of muscarinic receptor antagonists and their use for treating spasm of smooth muscle in the urological field |
| 01/25/2001 | DE19934433A1 New N-(indolyl-carbonyl)-N'-ethyl-piperazine derivatives, are 5-HT-2A receptor antagonists useful e.g. for treating schizophrenia, depression, Parkinson's disease, Alzheimer's disease or anorexia |
| 01/25/2001 | DE19933926A1 Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel Biphenyl derivatives, their preparation and their use as medicaments |
| 01/25/2001 | DE19933506A1 Zelluläre Aufnahme von DNA Cellular uptake of DNA |
| 01/25/2001 | DE19933421A1 2-Benzyl-3-dimethylamino-1-phenyl-propanderi- vate 2-benzyl-3-dimethylamino-1-phenyl-propanderi- derivatives |
| 01/25/2001 | DE19933164A1 Neue Carbonsäurederivate mit 5,6 substituiertem Pyrimidinring, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten New carboxylic acid derivatives with 5,6-substituted pyrimidine ring, their preparation and use as endothelin receptor antagonists |
| 01/25/2001 | DE19933148A1 Ambroxolhaltige Lutschtablette Ambroxol lozenge |
| 01/25/2001 | CA2616704A1 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 01/25/2001 | CA2380727A1 Nitrogen containing heterobicycles as factor xa inhibitors |
| 01/25/2001 | CA2379983A1 Dsp-11 dual-specificity map kinase phosphatase |
| 01/25/2001 | CA2379968A1 Gtp-binding protein associated factors |
| 01/25/2001 | CA2379891A1 Quaternary bis-ammonium salt precursors and their uses as prodrugs having an antiparasitic activity |
| 01/25/2001 | CA2379847A1 Method for making debromohymenialdisine and analogs thereof |
| 01/25/2001 | CA2379662A1 Preventive and therapeutic agents for cancer |
| 01/25/2001 | CA2379657A1 Phosphate transport inhibitors |
| 01/25/2001 | CA2379653A1 Pharmaceutical composition for topical application, uses and process for the preparation thereof |
| 01/25/2001 | CA2379577A1 Remedies or preventives for frequent urination or urinary incontinence |
| 01/25/2001 | CA2379554A1 Benzimidazolone derivatives and their use as phosphodiesterase inhibitors |
| 01/25/2001 | CA2379545A1 Novel carboxylic acid derivatives with 5,6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists |
| 01/25/2001 | CA2379489A1 Procyanidin oligomers inhibiting matrix metalloproteinases and medicine having effective composition of the same |
| 01/25/2001 | CA2379391A1 Modulation of human sodium channels in dorsal root ganglia |
| 01/25/2001 | CA2379336A1 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 01/25/2001 | CA2379319A1 Aminobenzophenones as inhibitors of il-1.beta. and tnf-.alpha. |
| 01/25/2001 | CA2379316A1 Novel aminobenzophenones |
| 01/25/2001 | CA2379308A1 Fat-binding polymers, optionally combined with lipase inhibitors |
| 01/25/2001 | CA2379293A1 Aminobenzophenones as inhibitors of il-1.beta. and tnf-.alpha. |
| 01/25/2001 | CA2379286A1 Aminobenzophenones as inhibitors of il-1.beta. and tnf-.alpha. |
| 01/25/2001 | CA2379273A1 Aminobenzophenones as inhibitors of il-1.beta. and tnf-.alpha. |
| 01/25/2001 | CA2379223A1 Orally active androgens |
| 01/25/2001 | CA2379208A1 Spla2 inhibitors |
| 01/25/2001 | CA2379140A1 Use of a tacrolimus analogue as a neuroprotective agent |
| 01/25/2001 | CA2379064A1 Bradykinin b1 receptor antagonists |
| 01/25/2001 | CA2379041A1 Diacylhydrazine derivatives |
| 01/25/2001 | CA2378946A1 Psca: prostate stem cell antigen and uses thereof |
| 01/25/2001 | CA2378917A1 Melanin-concentrating hormone receptor |
| 01/25/2001 | CA2378829A1 Sustained release drug dispersion delivery device |
| 01/25/2001 | CA2378723A1 3-amino-2-benzyl-1-phenyl-propane derivatives |
| 01/25/2001 | CA2378430A1 Methods and apparatus for preparation of lipid vesicles |
| 01/25/2001 | CA2378381A1 Method for treating chronic pain using mek inhibitors |
| 01/25/2001 | CA2378336A1 Rapid immediate release oral dosage form |
| 01/25/2001 | CA2378202A1 New compounds |
| 01/25/2001 | CA2378181A1 Conjugates of sodium channel blockers and methods of using the same |
| 01/25/2001 | CA2378084A1 Novel diphenyl-piperidine derivate |
| 01/25/2001 | CA2378047A1 Heterocyclic compounds for the treatment of migraine |
| 01/25/2001 | CA2378026A1 Novel glycosyl sulfotransferases gst-4.alpha., gst-4.beta., and gst-6 |
| 01/25/2001 | CA2377718A1 1,2,3,4,5,6-hexahydroazepino¬4,5-b|indoles containing arylsulfones at the 9-position |
| 01/25/2001 | CA2377247A1 Activation and protection of cytotoxic lymphocytes using a reactive oxygen metabolite inhibitor |
| 01/25/2001 | CA2377100A1 Method for treating chronic pain using mek inhibitors |
| 01/25/2001 | CA2377092A1 Method for treating chronic pain using mek inhibitors |
| 01/25/2001 | CA2376521A1 Sunscreen for the scalp and hair |
| 01/25/2001 | CA2376518A1 Conversion of a watson-crick dna to a hoogsteen-paired duplex |
| 01/25/2001 | CA2375980A1 Compositions, kits, and methods for providing and maintaining energy and mental alertness |